Rating Change
Barclays reiterated its Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) on August 13, 2026.
reiterateNASDAQ:CYTK
Barclays Reiterates Overweight Rating on Cytokinetics, Incorporated (CYTK)
Barclays reiterated its Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) on August 13, 2026.
At publication ·
What changed
Cytokinetics, Incorporated (NASDAQ:CYTK) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $73.45
- Market capitalization
- $7.2B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on Cytokinetics (CYTK) on August 13, 2026, with the stock trading at $73.45 and a market capitalization of $7.2 billion.
Market Context
Cytokinetics, Incorporated operates in the Healthcare sector. The stock currently trades at $73.45 with a market capitalization of $7.2B. The stock has gained 99.2% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cytokinetics, Incorporated.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Cytokinetics, Incorporated
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 13, 2026 | JP Morgan | Overweight | N/A |
| Aug 13, 2026 | Barclays | Overweight | N/A |
| Aug 10, 2026 | Truist Securities | Buy | N/A |
| Aug 07, 2026 | RBC Capital | Outperform | N/A |
| Aug 07, 2026 | Citizens | Market Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CYTK Stock Page
Frequently Asked Questions
What does the Overweight rating mean for CYTK?
A rating of Overweight from Barclays reflects the analyst's outlook on Cytokinetics, Incorporated (NASDAQ:CYTK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CYTK forecast page.